- Home
- JRI vs ETON Comparison
JRI vs ETON Comparison
Compare JRI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRI
- ETON
- Stock Information
- Founded
- JRI 2012
- ETON 2017
- Country
- JRI United States
- ETON United States
- Employees
- JRI N/A
- ETON N/A
- Industry
- JRI Finance Companies
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- JRI Finance
- ETON Health Care
- Exchange
- JRI Nasdaq
- ETON Nasdaq
- Market Cap
- JRI N/A
- ETON 329.8M
- IPO Year
- JRI N/A
- ETON 2018
- Fundamental
- Price
- JRI $12.84
- ETON $12.50
- Analyst Decision
- JRI
- ETON Strong Buy
- Analyst Count
- JRI 0
- ETON 3
- Target Price
- JRI N/A
- ETON $27.67
- AVG Volume (30 Days)
- JRI 68.0K
- ETON 222.5K
- Earning Date
- JRI 01-01-0001
- ETON 05-08-2025
- Dividend Yield
- JRI 9.38%
- ETON N/A
- EPS Growth
- JRI N/A
- ETON N/A
- EPS
- JRI N/A
- ETON N/A
- Revenue
- JRI N/A
- ETON $39,011,000.00
- Revenue This Year
- JRI N/A
- ETON $92.33
- Revenue Next Year
- JRI N/A
- ETON $52.62
- P/E Ratio
- JRI N/A
- ETON N/A
- Revenue Growth
- JRI N/A
- ETON 23.29
- 52 Week Low
- JRI $9.70
- ETON $3.03
- 52 Week High
- JRI $12.12
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- JRI 46.06
- ETON 36.53
- Support Level
- JRI $12.81
- ETON $12.24
- Resistance Level
- JRI $13.05
- ETON $13.46
- Average True Range (ATR)
- JRI 0.16
- ETON 0.94
- MACD
- JRI -0.02
- ETON -0.15
- Stochastic Oscillator
- JRI 7.81
- ETON 10.03
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.